Technology to treat covid and other pneumonias, toxic lung diseases, new generation mechanical ventilation.

New generation Mechanical Ventilation 2.0, hypothetically offering better clinical and financial outcomes, at similar cost.

Facebook Twitter LinkedIn

Team comprises of two members, founder and inventor Lukasz Kiljanek MD, and CTO Elżbieta Haftek PhD

Łukasz Kiljanek M.D. is a board certified in Internal Medicine, Nephrology and Hypertension. Experienced in Intensive care, Pulmonary, Chest surgery and Cardiology. Clinical researcher,  AI and data mining, and programmer

Elżbieta Haftek PhD is engineer, R&D, reliability, system engineering, data science. Ph.D. Material  Science and Engineering, M.Sc. Medical Device Innovation (UoM), MILI Fellow at the Carlson School of Management

 We want to develop, test, and deliver to market, or to exit, a new generation mechanical ventilator, we like to call Mechanical Ventilator 2.0. Please find out more about the invention, on our startup profile website.

We are the concept / basic prototype level. For simplicity we didn't form yet company. 

The purpose of this description is to illustrate the concepts, unproven yet benefits of and the fundamentals of the invention “Mechanical Ventilation v2.0” in order to find partners and sponsors who might be interested in further development of the technology, or buyers, who might be interested in purchasing the IP.


  • Each year, before covid, there were about ~ 2 million ventilated Intensive Care Units (ICU) patients in USA

  • Ventilated patients usually have high mortality (50%) and for some diseases even higher (COVID 26-97%, H1N1 influenza and others 25-46%)

  • Mechanical ventilation and complications renders ~ 2.5 x costs $ of ICU stay as of 2005

  • Patients on ventilators consume very high resources with high morbidity, with longer ICU and hospital stays

  • Mechanical ventilation now 50 + years, with no major developments in its foundations

Our invention and product may offer solution. It is new paradigm of mechanical ventilation, we call it Mechanical Ventilation 2.0. It was inspired with reports of patients doing exceptionally very poorly once placed on ventilator. 

Main features of Mechanical Ventilation 2.0:

  • Separate inspiratory and expiratory lumen(s) prevents re-breathing of contaminated air and allow for functional separation of lungs portions, which can prevent cross-contamination of i.e. infected air from sick left lung to healthy or healthy yet right lung

  • Continuous variable flows via inspiratory and expiratory lumens provide clearance of dead space and suspended within diseases causative agents (i.e. covid virions, toxins), allowing for full recovery, and eliminates reinfection of recovered alveoli / pneumocytes

  • More inflow via inspiratory lumens than outflow via expiratory lumens results in inspiration

  • More outflow via expiratory lumens than inflow via inspiratory lumens results in expiration

  • Operator can independently adjust the amount of delivered O2 and cleared amount of CO2
    • benefit in ARDS, no need to implement permissive hypercapnia with effective respiratory acidosis
    • benefit in severe COPD exacerbation with massive CO2 retention

  • Adapter allowing to use some benefits of our technology with existing “vents”  included in our Intellectual Property portfolio

  • Please see the following video for more details and explanations :

Postulated benefits of the technology:

  • better clinical outcomes, including:
    • mortality, 
    • prevention of ventilator associated pneumonia
    • no need to implement permissive hypercapnia in ARDS
    • ability to independently set goal pO2 and pCo2
    • down-stream benefits, less antibiotics use, less clostridium difficile infections

  • better financial outcomes
    • shorter “on-ventilator” time, 
    • shorter ICU stay, 
    • shorter hospital stay, 
    • faster recovery, 
    • shorter “back-to-work” time, 
    • less healthcare resources utilization
    • possibly higher reimbursement in institutions with better clinical outcomes (i.e. due to less clostridium difficile infection)

  • safer for staff 
    • separation of inspiratory and exploratory lumens prevents release of pathogens into the patient room / ICU atmosphere, as patients can be suctioned using only inspiratory lumens, the expiatory lumens can be used as suctioning tubes anyways in a close-circuit fashion

  • no staff steep learning curve needed
    • similar procedures to place patient on ventilator, and off ventilator
    • similar concept about ventilator management
  • comparable price to current mechanical ventilators
  • with adapters, which concepts are within our Intellectual Property Portfolio, technology can be easily extended to currently used ventilators

What we have accomplished until now:

  • Provisional patent applications filed Aug-Oct 2020, by employer after internal experts evaluation. 
  • Patent ownership transferred to author upon author request
  • Non-provisional filling and PCT accomplished as of June 2021

  • We have a simplified model / prototype.
  • We proved some concepts and some feasibility subjectively.
  • See more details, pictures, videos and presentation :

Why we need investors, and how much money we need to raise:

  • Financing (200-250K $) to build a prototype of ventilator and endotracheal tubes, with “lungs” model and protecting international Intellectual Property protection
  • We need prototype and lungs model to performer rigorous, quantitative and objective proof of concept, accurate estimation of particulate clearance from airways in various ventilatory modes and with various inspiratory / expiratory lumens configuration
  • We would like to form LLC, where investors would acquire shares (ultimately), however with current estimated value of the invention of 2 500 000$, the 250 000$ would grant 10% of shares to investors, this is negotiable and we are opened to all offers.
  • Investors are welcome to serve as mentors and part of the team, this is negotiable and we are opened to all offers.
  • We would also consider much less monetary investment for shares, from person with skills, time and knowledge to become part of the team.
  • Alternatively, the invention and entire IP is for sale for 2 500 000$, this is negotiable and we are opened to all offers.
  • No offers, deals, sales, acquisitions are valid, until they are expressed in writing and signed by both parties in the presence of notary public.

Mentorship and networking:

  • Developing the proof of concept prototype, collaboration, quantitative and subjective testing of the concept, securing more funding for further development, and then animal, clinical studies and marketing. 

  • Please see the following video for more details and explanations :

Our basic prototype pictures, and current state of development:

Explanatory video:

USPTO and PTC patent applications for download and review:

Ready to Ask For Funding for your company?

Post a Funding Request